US2011060146A1PendingUtilityA1

Vitamin-d-like compounds

Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Jun 9, 2005Filed: Nov 15, 2010Published: Mar 10, 2011
Est. expiryJun 9, 2025(expired)· nominal 20-yr term from priority
A61P 9/10A61P 7/00A61P 35/02A61P 37/02A61P 37/06A61P 5/18A61P 35/00A61P 27/02A61P 3/14A61P 25/00A61P 29/00A61P 3/00A61P 3/10A61P 25/28A61P 3/02C07D 333/16C07D 213/55C07C 2601/14C07D 237/08A61P 19/08C07D 309/10C07C 65/19A61P 17/14C07C 59/48A61P 19/02C07D 307/68C07C 59/68C07C 309/65A61P 17/00A61P 13/08C07C 271/22A61P 19/10C07D 307/42C07C 259/10A61P 17/02C07C 2601/18A61P 17/06A61P 13/12C07D 239/26A61P 17/16C07D 409/10C07C 59/64A61P 21/00C07D 277/30C07D 405/10C07C 59/54C07C 59/90C07C 59/56A61P 17/10C07C 2601/08C07C 51/00C07F 5/025C07D 335/02C07C 229/36C07D 307/54C07C 259/06
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

Claims

exact text as granted — not AI-modified
1 .- 34 . (canceled) 
     
     
         35 . A compound represented by the following general formula (II): 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  and R 2  independently represent an optionally substituted C 1-6  haloalkyl group, an optionally substituted C 2-6  alkenyl group, an optionally substituted C 2-6  alkynyl group or an optionally substituted C 1-6  alkoxy group, or R 1  and R 2  are taken together to form an optionally substituted C 3-8  cycloalkyl group; 
 R 3 , R 4 , R 5  and R 6  independently represent a hydrogen atom, a halogen atom, an optionally substituted C 1-6  alkyl group, a C 1-6  haloalkyl group, an optionally substituted C 2-6 , alkenyl group, an optionally substituted C 2-6  alkynyl group or an optionally substituted C 1-6  alkoxy group; 
 R 21  and R 22  independently represent a hydrogen atom or an optionally substituted C 1-6  alkyl group, or R 21  and R 22  are taken together with oxygen atoms and a boron atom to which they belong to form a 4- to 12-membered dioxaborane ring optionally substituted with a C 1-6  alkyl group; and 
 R 23  is a hydroxyl group, an optionally substituted C 6-12  aryl group, an optionally substituted 3- to 12-membered heterocycle, an optionally substituted C 1-6  alkoxy group or a group represented by the following general formula (III): 
 
       
         
           
           
               
               
           
         
       
       wherein R 7 , R 8  and R 9  independently represent a hydrogen atom, an optionally protected hydroxyl group, an optionally substituted amino group, an optionally substituted carboxyl group, an optionally substituted C 1-10  alkyl group or a C 1-6  haloalkyl group, or anyone pair of (R 7  and R 8 ), (R 7  and R 9 ) and (R 8  and R 9 ) are taken together to form an optionally substituted C 3-10  cycloalkyl group, a carbonyl group, an optionally substituted 3- to 12-membered heterocycle or a C 3-7  lactone; X is a direct bond, methylene, ethylene, vinylene, ethynylene, —O—, —S—, —NH—, carbonyl, an optionally substituted C 6-12  aryl group or an optionally substituted 3- to 12-membered heterocycle; and
 a represents an integer of 0 to 3, or a chemically acceptable salt thereof. 
 
     
     
         36 . The compound according to claim  1 , wherein R 23  is a group represented by the general formula (III), or a chemically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2011060146A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.